Top Markets
Coin of the day
Theradiag S.A. Theradiag S.A.

Theradiag S.A.

ALTER
Rang in aandelen #31653
Theradiag S.A. specializes in the creation, production, and marketing of... Theradiag S.A. specializes in the creation, production, and marketing of in-vitro diagnostic solutions. Its product line encompasses reagents for autoimmune conditions, IMMUNO-TROL — a comprehensive quality control tool with multiple parameters — and various instruments for testing both autoimmune disorders and infectious diseases. Among its unique offerings are the SQA-V system, engineered for semen analysis, and V-Sperm, a specialized application for digitally uploading and viewing sample results, including pictures and video recordings. The company's advanced instrumentation includes Theralis, which integrates multiplex FIDIS immunofluorescence with ELISA capabilities; Theralis µ, designed as a suitable solution for mid-sized laboratories; and the FIDIS platform, utilized for diverse laboratory analyses. Furthermore, Theradiag provides therapeutic drug monitoring services aimed at managing chronic inflammatory conditions. It also offers LISA tracker, an essential device for overseeing biotherapies, alongside both ELISA and rapid serological tests for SARS-CoV-2. Founded in 1986, Theradiag S.A. is based in Marne La Vallee, France.
Aandeelprijs
$1.38
Laatst gesynchroniseerd: 2023-12-19
Marktkapitalisatie
$12.52M
Verandering (1 dag)
0.57%
Verandering (1 jaar)
0.00%
Land
FR
Handel Theradiag S.A. (ALTER)

Categorie

P/S-ratio voor Theradiag S.A. (ALTER)
P/S-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Theradiag S.A. is de huidige P/S-ratio (TTM) 0. Eind 2026 had het bedrijf een P/S-ratio van 0.
P/S-ratiohistoriek voor Theradiag S.A. van 2026 tot 2026
P/S-ratio aan het einde van elk jaar
Jaar P/S-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/S-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/S-ratio Verschil in P/S-ratio Land
4.13 -
US
5.03 -
US
2.78 -
IE
3.67 -
US
8.10 -
US